{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:19Z","timestamp":1794047419314,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.281607","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:15:37Z","timestamp":1669299337000},"page":"1168-1172","source":"Crossref","is-referenced-by-count":13,"title":["&lt;i&gt;IDH&lt;\/i&gt; mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy"],"prefix":"10.3324","volume":"108","author":[{"given":"Rami","family":"Komrokji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"46873","doi-asserted-by":"crossref","unstructured":"Volpe VO, Garcia-Manero G, Komrokji RS. Myelodysplastic syndromes: a new decade. Clin Lymphoma Myeloma Leuk. 2022; 22(1):1-16.","DOI":"10.1016\/j.clml.2021.07.031"},{"key":"46874","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"46875","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Stone RM, Al-Kali A. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Canc Netw. 2017; 15(1):60-87.","DOI":"10.6004\/jnccn.2017.0007"},{"key":"46876","doi-asserted-by":"crossref","unstructured":"Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021; 11(6):107-107.","DOI":"10.1038\/s41408-021-00497-1"},{"key":"46877","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Hanson CA, Hodnefield JM. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. Leukemia. 2012; 26(1):101-105.","DOI":"10.1038\/leu.2011.298"},{"key":"46878","doi-asserted-by":"crossref","unstructured":"Ades L, Dimicoli-Salazar S, Sebert M. Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS) : the ideal phase 2 study by the GFM group. Blood. 2021; 138(Suppl 1):S63.","DOI":"10.1182\/blood-2021-147898"},{"key":"46879","doi-asserted-by":"crossref","unstructured":"Sebert M, Cluzeau T, Beyne Rauzy O. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the Idiome phase 2 study by the GFM group. Blood. 2021; 138(Suppl 1):S62.","DOI":"10.1182\/blood-2021-146932"},{"key":"46880","doi-asserted-by":"crossref","unstructured":"Sallman DA, Komrokji R, Vaupel C. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016; 30(3):666-673.","DOI":"10.1038\/leu.2015.304"},{"key":"46881","doi-asserted-by":"crossref","unstructured":"Volpe VO, Komrokji RS. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?. Ther Adv Hematol. 2021; 12:2040620720986641.","DOI":"10.1177\/2040620720986641"},{"key":"46882","doi-asserted-by":"crossref","unstructured":"Hutzschenreuter F, Monsef I, Kreuzer KA, Engert A, Skoetz N. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes. Cochrane Database Syst Rev. 2016; 2:CD009310.","DOI":"10.1002\/14651858.CD009310.pub2"},{"key":"46883","doi-asserted-by":"crossref","unstructured":"Komrokji RS, Mailloux AW, Chen DT. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014; 99(7):1176-1183.","DOI":"10.3324\/haematol.2012.083345"},{"key":"46884","doi-asserted-by":"crossref","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-232.","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"46885","doi-asserted-by":"crossref","unstructured":"Tsaknakis G, Galli A, Papadakis S. Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. Blood. 2021; 138(14):1249-1257.","DOI":"10.1182\/blood.2021010815"},{"key":"46886","unstructured":"Bernard E, Tuechler H, Greenberg PL. Molecular international prognosis scoring system for myelodysplastic syndromes. NEJM Evid. 2022; 1(7)"},{"key":"46887","doi-asserted-by":"crossref","unstructured":"Nazha A, Komrokji R, Meggendorfer M. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021; 39(33):3737-3746.","DOI":"10.1200\/JCO.20.02810"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281607\/75072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281607\/75506","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10880\/75072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:49Z","timestamp":1794045769000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281607","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,24]]}}}